Actively Recruiting
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Led by Akeso · Updated on 2023-11-18
90
Participants Needed
1
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.
CONDITIONS
Official Title
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically confirmed Gastric or Gastroesophageal Junction Adenocarcinoma
- Stage T3-4N+M0 Gastric or Gastroesophageal Junction Adenocarcinoma (AJCC)
- Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Adequate organ function
You will not qualify if you...
- Suspected metastases or locally advanced, unresectable disease
- Currently participating in a study of an investigational agent or using an investigational device
- Major surgery within 30 days before Study Day 1
- Active autoimmune disease requiring systemic treatment in the past 2 years
- Known active Hepatitis B or Hepatitis C infection
- History of myocardial infarction, unstable angina, or congestive heart failure within 12 months prior to study treatment
- Known psychiatric or substance abuse disorders interfering with study cooperation
- Received live virus vaccine within 30 days before planned first dose of study therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Provincial Tumor Hospital
Tianjin, China
Actively Recruiting
Research Team
W
Weifeng Song, MD
CONTACT
H
Han Liang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here